Search and Contain : Impact of an Integrated Genomic and Epidemiological Surveillance and Response Program for Control of Carbapenemase-producing Enterobacterales
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America..
BACKGROUND: Multiresistant organisms (MROs) pose a critical threat to public health. Population-based programs for control of MROs such as carbapenemase-producing Enterobacterales (CPE) have emerged and evaluation is needed. We assessed the feasibility and impact of a statewide CPE surveillance and response program deployed across Victoria, Australia (population 6.5 million).
METHODS: A prospective multimodal intervention including active screening, carrier isolation, centralized case investigation, and comparative pathogen genomics was implemented. We analyzed trends in CPE incidence and clinical presentation, risk factors, and local transmission over the program's first 3 years (2016-2018).
RESULTS: CPE case ascertainment increased over the study period to 1.42 cases/100 000 population, linked to increased screening without a concomitant rise in active clinical infections (0.45-0.60 infections/100 000 population, P = .640). KPC-2 infection decreased from 0.29 infections/100 000 population prior to intervention to 0.03 infections/100 000 population in 2018 (P = .003). Comprehensive case investigation identified instances of overseas community acquisition. Median time between isolate referral and genomic and epidemiological assessment for local transmission was 11 days (IQR, 9-14). Prospective surveillance identified numerous small transmission networks (median, 2; range, 1-19 cases), predominantly IMP and KPC, with median pairwise distance of 8 (IQR, 4-13) single nucleotide polymorphisms; low diversity between clusters of the same sequence type suggested genomic cluster definitions alone are insufficient for targeted response.
CONCLUSIONS: We demonstrate the value of centralized CPE control programs to increase case ascertainment, resolve risk factors, and identify local transmission through prospective genomic and epidemiological surveillance; methodologies are transferable to low-prevalence settings and MROs globally.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 73(2021), 11 vom: 06. Dez., Seite e3912-e3920 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lane, Courtney R [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.03.2022 Date Revised 04.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciaa972 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312398220 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312398220 | ||
| 003 | DE-627 | ||
| 005 | 20240404232304.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaa972 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM312398220 | ||
| 035 | |a (NLM)32663248 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lane, Courtney R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Search and Contain |b Impact of an Integrated Genomic and Epidemiological Surveillance and Response Program for Control of Carbapenemase-producing Enterobacterales |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2022 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: Multiresistant organisms (MROs) pose a critical threat to public health. Population-based programs for control of MROs such as carbapenemase-producing Enterobacterales (CPE) have emerged and evaluation is needed. We assessed the feasibility and impact of a statewide CPE surveillance and response program deployed across Victoria, Australia (population 6.5 million) | ||
| 520 | |a METHODS: A prospective multimodal intervention including active screening, carrier isolation, centralized case investigation, and comparative pathogen genomics was implemented. We analyzed trends in CPE incidence and clinical presentation, risk factors, and local transmission over the program's first 3 years (2016-2018) | ||
| 520 | |a RESULTS: CPE case ascertainment increased over the study period to 1.42 cases/100 000 population, linked to increased screening without a concomitant rise in active clinical infections (0.45-0.60 infections/100 000 population, P = .640). KPC-2 infection decreased from 0.29 infections/100 000 population prior to intervention to 0.03 infections/100 000 population in 2018 (P = .003). Comprehensive case investigation identified instances of overseas community acquisition. Median time between isolate referral and genomic and epidemiological assessment for local transmission was 11 days (IQR, 9-14). Prospective surveillance identified numerous small transmission networks (median, 2; range, 1-19 cases), predominantly IMP and KPC, with median pairwise distance of 8 (IQR, 4-13) single nucleotide polymorphisms; low diversity between clusters of the same sequence type suggested genomic cluster definitions alone are insufficient for targeted response | ||
| 520 | |a CONCLUSIONS: We demonstrate the value of centralized CPE control programs to increase case ascertainment, resolve risk factors, and identify local transmission through prospective genomic and epidemiological surveillance; methodologies are transferable to low-prevalence settings and MROs globally | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a antimicrobial resistance | |
| 650 | 4 | |a carbapenemase-producing Enterobacterales | |
| 650 | 4 | |a genomics | |
| 650 | 4 | |a infection control | |
| 650 | 4 | |a public health surveillance | |
| 650 | 7 | |a Bacterial Proteins |2 NLM | |
| 650 | 7 | |a beta-Lactamases |2 NLM | |
| 650 | 7 | |a EC 3.5.2.6 |2 NLM | |
| 650 | 7 | |a carbapenemase |2 NLM | |
| 650 | 7 | |a EC 3.5.2.6 |2 NLM | |
| 700 | 1 | |a Brett, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Schultz, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Gorrie, Claire L |e verfasserin |4 aut | |
| 700 | 1 | |a Stevens, Kerrie |e verfasserin |4 aut | |
| 700 | 1 | |a Cameron, Donna R M |e verfasserin |4 aut | |
| 700 | 1 | |a St George, Siobhan |e verfasserin |4 aut | |
| 700 | 1 | |a van Diemen, Annaliese |e verfasserin |4 aut | |
| 700 | 1 | |a Easton, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Stuart, Rhonda L |e verfasserin |4 aut | |
| 700 | 1 | |a Sait, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Peleg, Anton Y |e verfasserin |4 aut | |
| 700 | 1 | |a Stewardson, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Allen C |e verfasserin |4 aut | |
| 700 | 1 | |a Spelman, Denis W |e verfasserin |4 aut | |
| 700 | 1 | |a Waters, Mary Jo |e verfasserin |4 aut | |
| 700 | 1 | |a Ballard, Susan A |e verfasserin |4 aut | |
| 700 | 1 | |a Sherry, Norelle L |e verfasserin |4 aut | |
| 700 | 1 | |a Williamson, Deborah A |e verfasserin |4 aut | |
| 700 | 1 | |a Romanes, Finn |e verfasserin |4 aut | |
| 700 | 1 | |a Sutton, Brett |e verfasserin |4 aut | |
| 700 | 1 | |a Kwong, Jason C |e verfasserin |4 aut | |
| 700 | 1 | |a Seemann, Torsten |e verfasserin |4 aut | |
| 700 | 1 | |a Goncalves da Silva, Anders |e verfasserin |4 aut | |
| 700 | 1 | |a Stephens, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Howden, Benjamin P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 73(2021), 11 vom: 06. Dez., Seite e3912-e3920 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2021 |g number:11 |g day:06 |g month:12 |g pages:e3912-e3920 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciaa972 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2021 |e 11 |b 06 |c 12 |h e3912-e3920 | ||